Perceptive Advisors' SPAC ARYA Sciences Acquisition V files for a $130 million IPO

ARYA Sciences Acquisition V, the fifth healthcare-focused blank check company formed by Perceptive Advisors, filed on Thursday with the SEC to raise up to $130 million in an initial public offering.

The New York, NY-based company plans to raise $130 million by offering 13 million shares at $10 per share. The offering does not contain warrants. The company may raise an additional $25 million at the closing of an acquisition pursuant to a forward purchase agreement with the sponsor. At the proposed deal size, ARYA Sciences Acquisition V would command a market value of $167 million.

The company is led by Chairman Joseph Edelman, who serves as Founder and CEO of Perceptive Advisors; CEO and Director Adam Stone, who serves as Chief Investment Officer of Perceptive Advisors; and CFO and Director Michael Altman, who is a Managing Director at Perceptive Advisors. The team's previous SPACs include ARYA Sciences Acquisition IV (ARYD; +4.2% from offering price), which went public in February 2021; ARYA Sciences Acquisition III, which completed its acquisition with Nautilus Biotechnology (NAUT; -9.6%) in June 2021; ARYA Sciences Acquisition II, which completed its acquisition of Cerevel Therapeutics (CERE; +26%) in October 2020; and ARYA Sciences Acquisition, which completed its acquisition of Immatics Biotechnologies (IMTX; +17%) in July 2020.

ARYA Sciences Acquisition V plans to target the healthcare industry, with a specific focus on North American or European companies in the life sciences and medical technology sectors where management has extensive investment experience.

The company was founded in 2021 and plans to list on the Nasdaq under the symbol ARYE. ARYA Sciences Acquisition V filed confidentially on March 31, 2021. Jefferies, and Goldman Sachs are the joint bookrunners on the deal.